Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
NCCN Guidelines
National Comprehensive Cancer Network (NCCN)
Filter by Topic
NCCN 2017 Conference Highlights
NCCN 2019 Conference Highlights
NCCN 2020 Highlights
NCCN 2022 Hematologic Malignancies
NCCN 2022 Highlights
NCCN Guideline Updates
NCCN Hematologic Malignancies News
FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments
FDA Approvals, News & Updates
,
In the News
,
National Comprehensive Cancer Network (NCCN)
,
NCCN Guideline Updates
FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.
Read More ›
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
By
Wayne Kuznar
NCCN 2019 Conference Highlights
,
Leukemia
,
National Comprehensive Cancer Network (NCCN)
The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.
Read More ›
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
By
Wayne Kuznar
Breast Cancer
,
National Comprehensive Cancer Network (NCCN)
Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding. The updated National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of invasive breast cancer is focused on HR-positive, HER2-negative disease. William J. Gradishar, MD, Director, Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, discussed the updated guideline at the NCCN 2019 Conference.
Read More ›
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
By
Wayne Kuznar
National Comprehensive Cancer Network (NCCN)
The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy. Pembrolizumab (Keytruda) is recommended as the preferred first-line immune checkpoint inhibitor for patients with ≥50% of tumor cells that express PD-L1. First-line immunotherapy is restricted to NSCLC without
EGFR
or
ALK
mutations.
Read More ›
Updated NCCN Guidelines Expand Targeted Therapy Options for Patients with Metastatic NSCLC
By
Wayne Kuznar
NCCN Guideline Updates
,
National Comprehensive Cancer Network (NCCN)
Read More ›
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
By
Wayne Kuznar
NCCN Guideline Updates
,
National Comprehensive Cancer Network (NCCN)
Read More ›
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
By
Wayne Kuznar
Immunotherapy
,
NCCN Guideline Updates
,
National Comprehensive Cancer Network (NCCN)
Read More ›
Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification
By
Wayne Kuznar
NCCN Guideline Updates
,
National Comprehensive Cancer Network (NCCN)
Read More ›
Treating Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
By
Corbin Davis
Hematologic Malignancies
,
Multiple Myeloma
,
NCCN Hematologic Malignancies News
,
National Comprehensive Cancer Network (NCCN)
Recent advances in the treatment of patients with multiple myeloma have dramatically altered the trajectory of the disease, as providers now have several efficacious agents in various drug classes at their disposal. At the 2017 NCCN Hematologic Malignancies Congress, Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN, provided management strategies for newly diagnosed multiple myeloma, including the role of autologous stem-cell transplant (ASCT) and posttransplant maintenance therapy.
Read More ›
Combination Therapies Dominate NCCN Guidelines for Multiple Myeloma
By
Wayne Kuznar
NCCN 2017 Conference Highlights
,
National Comprehensive Cancer Network (NCCN)
The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes